Meta Platforms Inc. (NASDAQ:META) shares declined following a strong earnings report, as investors weigh the impact of rising legal and regulatory costs that threaten its 82% gross margins.
"The youth mental health settlement, Texas privacy lawsuit and EU publisher compensation ruling all point to potentially higher legal, compliance and content costs over time," a Simply Wall St report noted on May 24.
The stock closed at $610.26, down 9.6 percent over the last 30 days. The slide comes after Chief Operating Officer Javier Olivan sold 1,466 shares on May 18 for approximately $893,000. While analysts maintain an average price target of $826.60, suggesting significant upside, recent insider selling and a string of legal battles have cooled investor sentiment.
The divergence between strong operating results and negative stock performance highlights a key risk for Meta: future growth may be constrained by the costs of litigation and compliance. The company is facing new rules on AI training data in Europe and a lawsuit from the Texas Attorney General over WhatsApp privacy, creating uncertainty around future outlays.
Regulatory Headwinds Mount
The company is navigating a complex and expensive web of legal challenges. In the U.S., Meta reached its first settlement with a school district over claims its social media platforms harmed student mental health. Simultaneously, the Texas Attorney General has filed a lawsuit accusing the company of misleading consumers about WhatsApp’s privacy protections.
In Europe, the pressure is just as intense. A European court has ruled that Meta must compensate publishers for news snippets used on its platforms and for training its AI models. Separately, to preempt antitrust action, Meta has offered rival AI chatbots free access to WhatsApp for one month. The EU is also planning new regulations targeting "addictive" design features like endless scrolling on platforms including Instagram.
Insider Sale Adds to Caution
Adding to investor concerns, Meta's COO Javier Olivan recently sold 1,466 shares valued at nearly $900,000. The transaction was executed under a Rule 10b5-1 trading plan adopted in November 2025. While such plans are set up in advance to avoid accusations of trading on non-public information, the sale from a top executive during a period of stock weakness has been noted by the market.
The negative reaction to a strong report suggests investors are now pricing in significant, long-term regulatory risk. While the stock appears undervalued by some metrics, with a P/E ratio of 21.9 and gross margins of 82 percent, traders will be closely watching for the financial impact of these legal challenges in upcoming quarterly reports.
This article is for informational purposes only and does not constitute investment advice.